Hall Michael J, Olopade Olufunmilayo I
Department of Medicine, Mailman School of Public Health, Columbia University, New York, NY, USA.
J Clin Oncol. 2006 May 10;24(14):2197-203. doi: 10.1200/JCO.2006.05.5889.
The impact of predictive genetic testing on cancer care can be measured by the increased demand for and utilization of genetic services as well as in the progress made in reducing cancer risks in known mutation carriers. Nonetheless, differential access to and utilization of genetic counseling and cancer predisposition testing among underserved racial and ethnic minorities compared with the white population has led to growing health care disparities in clinical cancer genetics that are only beginning to be addressed. Furthermore, deficiencies in the utility of genetic testing in underserved populations as a result of limited testing experience and in the effectiveness of risk-reducing interventions compound access and knowledge-base disparities. The recent literature on racial/ethnic health care disparities is briefly reviewed, and is followed by a discussion of the current limitations of risk assessment and genetic testing outside of white populations. The importance of expanded testing in underserved populations is emphasized.
预测性基因检测对癌症护理的影响可以通过对基因服务需求和利用的增加以及在降低已知突变携带者癌症风险方面取得的进展来衡量。尽管如此,与白人相比,在服务不足的种族和少数民族中,获得基因咨询和癌症易感性检测的机会以及利用情况存在差异,这导致临床癌症遗传学方面的医疗保健差距不断扩大,而这些差距才刚刚开始得到解决。此外,由于检测经验有限,服务不足人群中基因检测的效用存在缺陷,而且降低风险干预措施的有效性加剧了获取和知识库方面的差距。本文简要回顾了近期关于种族/民族医疗保健差距的文献,随后讨论了白人以外人群风险评估和基因检测目前存在的局限性。强调了在服务不足人群中扩大检测的重要性。